{
    "Clinical Trial ID": "NCT00802945",
    "Intervention": [
        "INTERVENTION 1: ",
        "  NKTR-102 14 Day",
        "  NKTR-102: NKTR-102 given on a q14 day schedule",
        "INTERVENTION 2: ",
        "  NKTR-102 21 Days",
        "  NKTR-102: NKTR-102 given on a q21 day schedule"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Inoperable metastatic or locally advanced breast cancer",
        "  No more than 2 prior chemotherapy regimens given in a metastatic or locally advanced setting and prior treatment in the metastatic setting must have included a taxane",
        "Exclusion Criteria:",
        "  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Day 1 of Cycle 1",
        "  Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle or minor surgery within 2 weeks prior to Day 1 of Cycle 1"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Objective Response Rate (ORR)",
        "  Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
        "  Time frame: Up to 2 years.",
        "Results 1: ",
        "  Arm/Group Title: NKTR-102 14 Day",
        "  Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of subjects  28.6        (14.6 to 46.3)",
        "Results 2: ",
        "  Arm/Group Title: NKTR-102 21 Days",
        "  Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of subjects  35        (14.6 to 46.3)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 18/35 (51.43%)",
        "  Anaemia * 0/35 (0.00%)",
        "  Febrile Neutropenia * 0/35 (0.00%)",
        "  Neutropenia * 1/35 (2.86%)",
        "  Vision Blurred * 1/35 (2.86%)",
        "  Abdominal Pain * 1/35 (2.86%)",
        "  Abdominal Pain Lower * 1/35 (2.86%)",
        "  Constipation * 0/35 (0.00%)",
        "  Diarrhoea * 6/35 (17.14%)",
        "  Ileitis * 0/35 (0.00%)",
        "  Nausea * 2/35 (5.71%)",
        "  Small Intestinal Obstruction * 0/35 (0.00%)",
        "Adverse Events 2:",
        "  Total: 15/35 (42.86%)",
        "  Anaemia * 1/35 (2.86%)",
        "  Febrile Neutropenia * 1/35 (2.86%)",
        "  Neutropenia * 0/35 (0.00%)",
        "  Vision Blurred * 0/35 (0.00%)",
        "  Abdominal Pain * 0/35 (0.00%)",
        "  Abdominal Pain Lower * 0/35 (0.00%)",
        "  Constipation * 1/35 (2.86%)",
        "  Diarrhoea * 4/35 (11.43%)",
        "  Ileitis * 1/35 (2.86%)",
        "  Nausea * 0/35 (0.00%)",
        "  Small Intestinal Obstruction * 1/35 (2.86%)"
    ]
}